Study of Lotilaner Ophthalmic Gel in Patients With Ocular Rosacea (KORE)
← catalyst calendarNCT07443202 · readout in 134 d
Sponsored by Tarsus Pharmaceuticals, Inc. (industry) · TARS — their whole pipeline →.
Phase
Phase 2
Status
Enrolling by invitation
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
155estimated
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-12-05 | actual | When the study began enrolling |
| Primary completion | 2026-12-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2026-03-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Ocular Rosacea
Interventions
- Drug: lotilaner
- Drug: Vehicle
Primary outcome
what the primary-completion date above is the date OFIncidence of Treatment Emergent Adverse Events
measured Week 16
Permalink · TARS's whole pipeline · Catalyst calendar · Every registered study · What changed